RET (A883F)
Sign in to save this workspaceRET · Variant type: point · HGVS: p.A883F
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Nintedanib | 100.0% | 0.0% | 90.23 |
| 2 | Ponatinib | 100.0% | 0.0% | 78.23 |
| 3 | Alectinib | 100.0% | 0.0% | 95.49 |
| 4 | Pralsetinib | 99.9% | 0.1% | 93.43 |
| 5 | Selpercatinib | 99.9% | 0.1% | 96.72 |
| 6 | Fedratinib | 99.8% | 0.2% | 96.21 |
| 7 | Tivozanib | 99.7% | 0.3% | 92.42 |
| 8 | Sorafenib | 99.6% | 0.4% | 96.72 |
| 9 | Alpelisib | 99.5% | 0.5% | 97.22 |
| 10 | Entrectinib | 99.4% | 0.6% | 93.69 |
| 11 | Vandetanib | 98.3% | 1.7% | 95.74 |
| 12 | Regorafenib | 98.2% | 1.8% | 95.99 |
| 13 | Brigatinib | 98.2% | 1.8% | 82.96 |
| 14 | Gilteritinib | 98.0% | 2.0% | 88.97 |
| 15 | Tenalisib | 97.9% | 2.1% | 97.98 |
| 16 | Lenvatinib | 97.9% | 2.1% | 97.74 |
| 17 | Repotrectinib | 97.5% | 2.5% | 84.21 |
| 18 | Cabozantinib | 97.2% | 2.8% | 92.73 |
| 19 | Avapritinib | 97.0% | 3.0% | 97.73 |
| 20 | Erdafitinib | 96.5% | 3.5% | 95.71 |
| 21 | Futibatinib | 96.4% | 3.6% | 98.48 |
| 22 | Pexidartinib | 95.8% | 4.2% | 99.49 |
| 23 | Ripretinib | 95.7% | 4.3% | 92.95 |
| 24 | Quizartinib | 94.7% | 5.3% | 99.50 |
| 25 | Apatinib | 93.1% | 6.9% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Nintedanib | 100.0% | 100.0% | +0.0% |
| Ponatinib | 100.0% | 100.0% | +0.0% |
| Alectinib | 100.0% | 97.8% | +2.2% |
| Pralsetinib | 99.9% | 100.0% | -0.1% |
| Selpercatinib | 99.9% | 100.0% | -0.1% |
| Fedratinib | 99.8% | 99.9% | -0.0% |
| Tivozanib | 99.7% | 99.7% | -0.1% |
| Sorafenib | 99.6% | 94.0% | +5.6% |
| Alpelisib | 99.5% | 99.6% | -0.1% |
| Entrectinib | 99.4% | 99.6% | -0.2% |
| Vandetanib | 98.3% | 98.6% | -0.3% |
| Regorafenib | 98.2% | 98.7% | -0.5% |
| Brigatinib | 98.2% | 94.9% | +3.3% |
| Gilteritinib | 98.0% | 100.0% | -2.0% |
| Tenalisib | 97.9% | 98.5% | -0.6% |
| Lenvatinib | 97.9% | 98.8% | -0.9% |
| Repotrectinib | 97.5% | — | — |
| Cabozantinib | 97.2% | 97.5% | -0.3% |
| Avapritinib | 97.0% | — | — |
| Erdafitinib | 96.5% | 94.7% | +1.9% |
| Futibatinib | 96.4% | 97.7% | -1.3% |
| Pexidartinib | 95.8% | — | — |
| Ripretinib | 95.7% | — | — |
| Quizartinib | 94.7% | — | — |
| Apatinib | 93.1% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_thyroid | Thyroid | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.1ms